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Abstract: Apolipoprotein (APO) E (ε) genotype is considered to play an important role in lipid responses
to dietary fat manipulation but the impact on novel cardiometabolic risk markers is unclear. To address
this knowledge gap, we investigated the relationship between theAPOE genotype and cardiometabolic
risk markers in response to acute and chronic dietary fat intakes. Associations with fasting (baseline)
outcome measures (n= 218) were determined using data from the chronic DIVAS (n= 191/195 adults at
moderate cardiovascular disease risk) and acute DIVAS-2 (n = 27/32 postmenopausal women) studies
examining the effects of diets/meals varying in saturated, polyunsaturated and monounsaturated
(MUFA) fatty acid composition. Participants were retrospectively genotyped for APOE (rs429358,
rs7412). For baseline cardiometabolic outcomes, E4 carriers had higher fasting total and low-density
lipoprotein-cholesterol (LDL-C), total cholesterol: high-density lipoprotein-cholesterol (HDL-C) and
LDL-C: HDL-C ratios, but lower C-reactive protein (CRP) than E3/E3 and E2 carriers (p ≤ 0.003).
Digital volume pulse stiffness index was higher in E2 carriers than the E3/E3 group (p = 0.011).
Following chronic dietary fat intake, the significant diet × genotype interaction was found for fasting
triacylglycerol (p = 0.010), with indication of a differential responsiveness to MUFA intake between the
E3/E3 and E4 carriers (p = 0.006). Test fat × genotype interactions were observed for the incremental
area under the curve for the postprandial apolipoprotein B (apoB; p = 0.022) and digital volume
pulse reflection index (DVP-RI; p = 0.030) responses after the MUFA-rich meals, with a reduction
in E4 carriers and increase in the E3/E3 group for the apoB response, but an increase in E4 carriers
and decrease in the E3/E3 group for the DVP-RI response. In conclusion, baseline associations
between the APOE genotype and fasting lipids and CRP confirm previous findings, although a
novel interaction with digital volume pulse arterial stiffness was observed in the fasted state and
differential postprandial apoB and DVP-RI responses after the MUFA-rich meals. The reported
differential impact of the APOE genotype on cardiometabolic markers in the acute and chronic state
requires confirmation.
Keywords: APOE; cardiometabolic risk markers; dietary fat; fat manipulation
1. Introduction
The apolipoprotein (APO) E (ε) genotype is the most widely researched single nucleotide
polymorphism in relation to cardiovascular disease (CVD) risk, with the APOE4 allele linked with
increased total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), CVD risk and
mortality [1–5]. The APOE genotype has also been reported to influence the fasting lipid profile in
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response to dietary fat intake. Studies to date have focused on high-fat, high saturated fatty acid (SFA),
low-fat and high-fat, high-SFA with fish oil interventions [6–12], whilst little is known of the interactions
between the APOE genotype with n-6 polyunsaturated (PUFA) and monounsaturated (MUFA) fatty
acid intakes. This is particularly important and timely given that population dietary recommendations
for CVD prevention advise the reduction of SFA intakes to ≤10% of total energy (%TE) via replacement
with n-6 PUFA or MUFA. Although fasting lipids contribute to the increased CVD risk they do not
seem to solely explain this increased risk in APOE4 carriers, with limited information available on
other cardiometabolic risk markers. In particular, endothelial dysfunction is now recognised as a key
modifiable event in coronary atherosclerosis, but limited data are available on the impact of APOE on
the responsiveness of vascular reactivity to dietary fat composition [13].
Most of the studies investigating the interaction between the APOE genotype with dietary fat
intake on lipid metabolism have been performed in the fasted state. However, postprandial lipaemia
is now recognised as an independent CVD risk factor [14–16], which is particularly relevant given
that individuals are in the fed state for the majority of the day. Previous studies have reported
polymorphisms in the APOE gene to be associated with increased postprandial triacylglycerol (TAG)
responses [17–19]. The Reading, Imperial, Surrey, Cambridge and Kings (RISCK) study reported
differential effects on the lipid response when SFA was replaced with MUFA and low glycaemic
index carbohydrates after a 24-week dietary intervention with variations in the APOE genotype [20].
However, data is extremely limited on the impact of meal fatty acids on postprandial lipid and vascular
outcomes according to the APOE genotype.
The present analysis explored the interaction of the APOE genotype with both chronic and acute
intake of diets/meals rich in SFA, MUFA or n-6 PUFA on established and novel cardiometabolic
risk markers. This was achieved using data form the chronic Dietary Intervention and Vascular
Function (DIVAS) study performed in 195 individuals with moderate CVD risk [21], and the DIVAS-2
postprandial study conducted in 32 postmenopausal women. We hypothesised that the APOE genotype
would influence these risk markers both at baseline and in response to fat manipulation. The overall
diet/meal fat effects for both studies will not be the focus of the current manuscript as these data have
been previously reported for each subject group [21,22].
2. Methods
2.1. Study Participants and Design
This paper was based on a retrospective APOE genotype analysis and previously analysed
cardiometabolic risk markers in participants from two studies (DIVAS and DIVAS-2) performed at
the Hugh Sinclair Unit of Human Nutrition (University of Reading, Reading, UK). The details of the
chronic DIVAS and acute DIVAS-2 studies have been previously published [21,22]. Only participants
who had provided informed consent for the retrospective genotyping for APOE were included in this
data analysis (n = 191 out of 195 participants for DIVAS and n = 27 out of 32 for DIVAS-2). Furthermore,
five women had participated in both the DIVAS and DIVAS-2 studies, so only baseline data from the
DIVAS study for these participants were included. Both studies were conducted in accordance with
the Declaration of Helsinki.
2.2. Baseline Associations Between APOE Genotype with Established and Novel Cardiometabolic Risk Markers
Baseline data (n = 218) from both the DIVAS (n = 84 men and n = 107 women) [21] and DIVAS-2
(n = 27 postmenopausal women) [21,22] studies were combined to investigate the impact of APOE
genotype on vascular function, blood pressure, biomarkers of endothelial dysfunction, lipids, glucose,
insulin and inflammatory markers determined in the fasting state. Habitual dietary intake according to
the APOE genotype was assessed using data extracted from 4-day weighed food diaries and analysed
using Dietplan (DIVAS: version 6.6; DIVAS-2: version 7; Forestfield, Horsham, UK).
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2.3. Impact of the APOE Genotype on the Responsiveness of Cardiometabolic Risk Markers
2.3.1. Chronic Dietary Fat Composition
The DIVAS study was a single-blind, parallel-group randomised controlled trial that replaced
9.5–9.6 %TE of dietary SFA with MUFA or n-6 PUFA for 16 weeks. Non-smoking women and men
(n = 191) aged 21–60 y identified as having moderate CVD risk were recruited in three cohorts
from November 2009 to June 2012 [23]. Participants were randomly assigned to follow one of three
intervention diets, stratified by sex, age, body mass index (BMI) and CVD risk score. The isoenergetic
diets (target compositions of total fat:SFA:MUFA:n-6 PUFA as %TE) were rich in SFA (36:17:11:4), MUFA
(36:9:19:4) or n-6 PUFA (36:9:13:10), and were matched for protein, carbohydrate and n-3 PUFA [23].
A flexible food-exchange model replaced sources of exchangeable fats in the diet with intervention
foods that had a specific fatty acid composition, which included oils, spreads, snacks, and dairy
products. Primary sources of exchangeable fats were: Butter (SFA-rich diet; Wyke Farms, Somerset,
UK); refined olive oil and MUFA-rich spread (MUFA-rich diet; Unilever R&D, Vlaardingen B.V,
Netherlands); saﬄower oil and n-6 PUFA-rich spread (n-6 PUFA-rich diet; Unilever R&D Vlaardingen
B.V, Netherlands). At baseline (week 0) and after the intervention period (week 16), macro-vascular
reactivity was assessed by conducting flow mediated dilatation (FMD) of the brachial artery and a
fasted blood sample was taken, as previously described [21]. This study was approved for conduct by
the West Berkshire Local Research Ethics Committee (09/H0505/56) and the Research Ethics Committee
at the University of Reading (project reference number 09/40), and registered as a clinical trial at
www.clinicaltrials.gov (NCT01478958).
2.3.2. Acute Meal Fat Composition
The DIVAS-2 study was an acute, double-blind, randomised, cross-over study conducted between
June 2014 and September 2015. Postmenopausal women (n = 32) were randomly assigned to consume
sequential mixed test meals (0 min, 50 g fat and 330 min, 30 g fat) that were rich in SFA, MUFA or n-6
PUFA on three different occasions that were 4–6 weeks apart. Test fats included butter (SFA meal),
refined olive oil and MUFA-rich spread (MUFA meal), and saﬄower oil and n-6 PUFA-rich spreads (n-6
PUFA meal). Details of the test meal fat composition and study procedures are given elsewhere [22].
Blood samples were collected regularly (every 30 min until 180 min, followed by every 60 min until
300 min) after breakfast until the participant was provided with lunch at 330 min. Blood samples
were then collected at 30 min intervals until 420 min, with the last sample being taken at 480 min.
In this study, FMD was performed at baseline (fasting), 180, 300 and 420 min, and clinic blood pressure,
laser Doppler imaging (LDI) with iontophoresis and digital volume pulse (DVP) at baseline, 240 and
450 min. This study was approved for conduct by the Research Ethics Committee at the University of
Reading (project reference number 14/16) and was registered at www.clinicaltrials.gov (NCT02144454).
2.4. Vascular Reactivity Measurements and Blood Pressure
For both DIVAS and DIVAS-2 studies, macro- and micro-vascular reactivity were assessed by
conducting FMD of the brachial artery (primary outcome measure) and LDI with iontophoresis,
respectively [24]. In the peripheral arteries, DVP (Pulse Trace PCA2; Micro Medical Ltd., Chatham,
UK) assessed arterial stiffness and vascular tone by measuring the stiffness index (DVP-SI; m/s) and
reflection index (DVP-RI; %), respectively [24]. In DIVAS, 24 h ambulatory blood pressure (ABP) and
heart rate measurements were taken at 30 min intervals throughout the day and 60 min intervals
during the night at baseline and week 16 using A/A grade automated oscillometric ABP monitors
(A & D Instruments Ltd., Abingdon, UK) as described elsewhere [21]. In DIVAS and DIVAS-2, clinic
measurements of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate were
recorded at each study visit using an OMRON blood pressure monitor (OMRON Healthcare UK Ltd.,
Milton Keynes, UK). The difference between the average systolic and diastolic blood pressures was
used to determine pulse pressure.
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2.5. Biochemical Analysis, Estimates of Insulin Sensitivity/Resistance and CVD Risk Score
Serum samples from both studies were used to determine lipids (TC, high density
lipoprotein-cholesterol (HDL-C), TAG, apolipoprotein (apo)B (DIVAS-2 only)), glucose, C-reactive
protein (CRP) and non-esterified fatty acids (NEFA) using an ILAB600 clinical autoanalyzer (reagents
and analyser: Werfen, UK, Warrington UK.; NEFA reagent: Alpha Laboratories, Eastleigh, UK; apoB
reagent: Randox Laboratories Ltd., Crumlin, UK). The Friedewald formula was used to estimate
fasting concentrations of LDL-C [25]. The use of commercial ELISA kits determined concentrations of
serum insulin (Dako UK Ltd.; Ely, UK), and plasma concentrations of soluble intercellular adhesion
molecule-1 (sICAM-1), soluble vascular cell adhesion molecule (sVCAM-1), P-selectin and E-selectin
(R & D Systems, Biotechne, Abingdon, UK). Plasma nitrite and nitrate levels were analysed with
ozone-based chemiluminescence [26] in the DIVAS study and Eicom NOx Analyser ENO-30 (Eicom;
San Diego, CA, USA) [27], which is a HPLC-based approach, was used in the DIVAS-2 study.
Using baseline measures, standard equations were used to calculate the homeostatic model
assessment-insulin resistance (HOMA-IR) and the revised quantitative insulin sensitivity check index
(rQUICKI) as measures of insulin resistance and insulin sensitivity, respectively [28]. Estimation of
10 y CVD risk was determined using the QRISK®2-2016 online risk calculator (https://qrisk.org/2017/).
2.6. DNA Extraction and Genotyping
The buffy coat was isolated from 9 mL of blood collected into K2EDTA blood collection tube, and
DNA was extracted using the Qiagen DNA Blood Mini Kit (Qiagen Ltd., Crawley, UK). APOE genotype
(E2/E4, E2/E3, E2/E2, E3/E3, E3/E4 or E4/E4) was determined retrospectively by allelic discrimination
using “Assay-on-Demand” single nucleotide polymorphism genotyping assays (rs7412 and rs429358;
Life Technologies, Paisley, UK).
2.7. Statistical Analysis
The DIVAS and DIVAS-2 studies were powered to detect a 2% (SD 2.3%, 80% power and
5% significance level) and 1.5% (SD 2.0%, 80% power and 5% significance level) difference in
%FMD response (primary outcome), requiring 171 and 28 participants, respectively. Secondary
outcome measures in both studies included arterial stiffness, microvascular reactivity, blood pressure,
serum lipid profile, circulating markers of endothelial activation and inflammation and estimates of
insulin sensitivity/resistance. The analysis presented in this manuscript is explorative, investigating
the interactions between APOE genotype with fat manipulation on the primary and secondary
outcome measures.
Data analysis was performed using the statistical analysis software SPSS, version 21 (SPSS Inc.,
Chicago, IL, USA). Results are presented in the text, tables and figure as means ± SEMs. p ≤ 0.05 was
considered significant. Data were checked for normality of distribution, and skewed variables were
normalized prior to statistical analysis. For the baseline data analysis, which included data from both
the DIVAS and DIVAS-2 studies, a univariate general linear model (analysis of covariance—ANCOVA)
was implemented using the baseline outcome measures as the dependent variables, with sex and
the APOE genotype included as fixed factors and age and BMI as covariates, to assess the APOE
genotype effect. If a significant genotype effect was observed, pairwise comparisons were carried out.
These included a Bonferroni correction in which p ≤ 0.017 was considered significant.
To determine the effects of chronic dietary fat manipulation (DIVAS), a general linear model
(ANCOVA) was used to determine the overall effect of diet and the APOE genotype on the primary
and secondary outcome measures. In this model, the post-intervention (week 16)—baseline (week 0)
difference was the dependent variable, with the genotype, sex and intervention diet as fixed factors,
and baseline value of the variable of interest, age and BMI included as covariates. The interaction term
was included in the model to assess the overall diet × APOE genotype interaction. If a significant
interaction was found, a general linear model was performed for the three diets to determine which
Nutrients 2019, 11, 2044 5 of 20
diets were different within each genotype group separately. When there was no overall diet effect
for each genotype group, independent t-tests were performed for the three diet groups separately to
identify whether there were any differences between the genotype groups.
Acute effects of test fat composition (DIVAS-2) on the time response profiles were analysed
using a mixed factor repeated measures ANOVA with test fat and time included as within-subject
factors and genotype as the between-group factor. Postprandial response summary measures were
expressed as area and incremental area under the curve (AUC and IAUC, respectively) over 420,
450 or 480 min. The IAUC denotes the specific response to the test meals irrespective of baseline
concentrations. For NEFA, AUC and IAUC were computed from the mean time of suppression until
the final postprandial time point (120–480 min). Non-parametric one-way repeated measures ANOVA
was used for the statistical analysis of IAUC with negative values and for any data that was not
normalized following transformation. If a significant test fat × genotype interaction was found, a
repeated measures ANOVA was performed in the two genotype groups separately, with a Bonferroni
correction (where p ≤ 0.017 was considered significant). An independent t-test compared the responses
to the different test fats between genotype groups, where values p ≤ 0.05 were significant.
3. Results
3.1. Baseline Associations between the APOE Genotype with Established and Novel Cardiometabolic
Risk Markers
Table 1 presents the baseline subject characteristics and cardiometabolic risk markers of the
216 participants (84 males and 132 females (self-reported menopausal status: 66 pre-, 8 peri- and 58
postmenopausal women)) according to the APOE genotype, which were presented as E2 carriers (E2/E2
and E2/E3, n = 30), the wild-type homozygous E3/E3 group (n = 128) and E4 carriers (E3/E4 and E4/E4,
n = 58). Individuals with the E2/E4 genotype were excluded from all data analyses due to the small
subject group (n = 2).
At baseline, there was no significant effect of genotype on the %FMD response (primary outcome).
For TC (p= 0.0001), LDL-C (p= 0.0001), TC:HDL-C ratio (p= 0.002) and LDL-C:HDL-C ratio (p= 0.0001),
a significant genotype effect was evident with lipid concentrations and ratios increasing in the order:
E2 carriers > E3/E3 group > E4 carriers (Table 1). There was also an influence of genotype on baseline
CRP (p = 0.002), with lower concentrations in E4 carriers compared with the wild-type group (p = 0.003)
and E2 carriers (p = 0.002). DVP-SI was found to be different between genotype groups (p = 0.027),
with a 17% higher DVP-SI in the E2 carriers than the E3/E3 group (p = 0.011). The APOE genotype
did not influence any of the other baseline characteristics or cardiometabolic risk markers (Table 1).
Habitual dietary intakes stratified according to the genotype (Table S1) showed differences in %TE of
trans fatty acids (p = 0.031), whereby intakes were greater in the E2 carriers than E3/E3 group (p = 0.043).
However, this difference was not significant after correcting for multiple comparisons (p ≥ 0.017).
Table 1. Baseline characteristics in the combined study group and according to the APOE genotype.
All (n = 216) E2 Carriers (n = 30) E3/E3 (n = 128) E4 Carriers (n = 58) P (Genotype) 1
Genotype Frequency (%) - 14 59 27
Characteristics
Sex, M/F 84/132 13/17 43/85 28/30
Age, y 46 ± 1 48 ± 2 45 ± 1 46 ± 2 0.537
Weight, kg 76.5 ± 1.0 78.2 ± 2.8 75.0 ± 1.2 78.9 ± 1.8 0.082
BMI, kg/m2 26.6 ± 0.3 27.7 ± 0.8 26.4 ± 0.3 26.5 ± 0.5 0.341
Waist circumference, cm 91.3 ± 0.8 96.2 ± 2.7 90.1 ± 1.0 91.3 ± 1.5 0.091
Waist:hip ratio 0.87 ± 0.01 0.90 ± 0.02 0.86 ± 0.01 0.88 ± 0.01 0.152
Clinic blood pressure
Systolic, mm Hg 119 ± 1 122 ± 3 119 ± 1 118 ± 2 0.432
Diastolic, mm Hg 74 ± 1 77 ± 1 74 ± 1 73 ± 1 0.193
Pulse pressure, mm Hg 45 ± 1 45 ± 2 45 ± 1 45 ± 1 0.873
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Table 1. Cont.
All (n = 216) E2 Carriers (n = 30) E3/E3 (n = 128) E4 Carriers (n = 58) P (Genotype) 1
Genotype Frequency (%) - 14 59 27
Biochemical profile and CVD risk
TC, mmol/L 5.49 ± 0.07 4.77 ± 0.20 a 5.49 ± 0.09 b 5.88 ± 0.13 c 0.0001
HDL-C, mmol/L 1.49 ± 0.02 1.43 ± 0.06 1.52 ± 0.03 1.47 ± 0.05 0.606
LDL-C, mmol/L 3.42 ± 0.06 2.73 ± 0.16 a 3.42 ± 0.07 b 3.77 ± 0.11 c 0.0001
TC: HDL-C ratio 3.84 ± 0.07 3.49 ± 0.19 a 3.77 ± 0.09 b 4.20 ± 0.16 c 0.002
LDL-C: HDL-C ratio 2.41 ± 0.06 2.02 ± 0.15 a 2.37 ± 0.07 b 2.72 ± 0.12 c 0.0001
TAG, mmol/L 1.27 ± 0.04 1.34 ± 0.13 1.21 ± 0.05 1.34 ± 0.10 0.551
NEFA, µmol/L 502 ± 12 525 ± 28 509 ± 17 472 ± 22 0.413
Glucose, mmol/L 5.09 ± 0.03 5.12 ± 0.07 5.05 ± 0.04 5.18 ± 0.07 0.527
Insulin, pmol/L 31.2 ± 1.3 36.4 ± 4.6 30.4 ± 1.6 30.2 ± 2.3 0.619
HOMA-IR 1.19 ± 0.05 1.41 ± 0.19 1.14 ± 0.06 1.18 ± 0.10 0.605
rQUICKI 0.45 ± 0.01 0.43 ± 0.01 0.45 ± 0.01 0.46 ± 0.01 0.238
QRISK®2, 2 % 2.8 ± 0.2 3.3 ± 0.7 2.4 ± 0.2 3.3 ± 0.4 0.142
Vascular function
%FMD response 6.2 ± 0.2 5.8 ± 0.5 6.4 ± 0.3 6.0 ± 0.4 0.698
LDI-Ach, AUC, PU 1548 ± 59 1529 ± 164 1523 ± 77 1601 ± 114 0.588
LDI-SNP, AUC, PU 1464 ± 50 1327 ± 106 1448 ± 64 1557 ± 105 0.370
DVP-RI, % 63.2 ± 0.9 64.8 ± 2.5 62.1 ± 1.1 64.8 ± 1.7 0.649
DVP-SI, m/s 6.9 ± 0.1 7.7 ± 0.5 a 6.6 ± 0.1 b 7.2 ± 0.2 a,b 0.027
Biomarkers of inflammation and endothelial activation
C-reactive protein, mg/L 2.23 ± 0.23 3.20 ± 0.70 a 2.27 ± 0.29 a 1.66 ± 0.41 b 0.002
sVCAM-1, ng/mL 661 ± 11 653 ± 23 652 ± 16 685 ± 20 0.400
sICAM-1, ng/mL 218 ± 3 228 ± 9 220 ± 4 207 ± 5 0.120
E-selectin, ng/mL 34.2 ± 1.0 31.4 ± 2.5 34.5 ± 1.3 35.0 ± 1.9 0.189
P-selectin, ng/mL 40.7 ± 1.0 37.3 ± 2.5 41.0 ± 1.3 41.8 ± 1.9 0.078
Values represent mean ± SEM, E2 carriers = E2/E2 and E2/E3; E4 carriers = E3/E4 and E4/E4. E2/E4 individuals were
excluded from the analysis. 1 Data analysed by univariate general linear model (analysis of covariance—ANCOVA)
adjusted for age, BMI and sex. If significant, pairwise comparisons were used to determine differences between
genotype groups. 2 QRISK®2 10 y risk of cardiovascular disease (https://qrisk.org/2017/) a, b, c Different superscript
letters within a row indicate significant differences between genotype groups (p ≤ 0.017). Abbreviations: Ach,
acetylcholine; PU, perfusion units; DBP, diastolic blood pressure; DVP-RI, digital volume pulse reflection index;
DVP-SI, digital volume pulse stiffness index; FMD, flow-mediated dilatation; HDL-C, high-density lipoprotein
cholesterol; HOMA-IR, quantitative insulin resistance index; LDI, laser Doppler imaging; AUC, area under the curve;
LDL-C, low-density lipoprotein cholesterol; NEFA, non-esterified fatty acids; rQUICKI, revised quantitative insulin
sensitivity index; SBP, systolic blood pressure; sICAM-1, soluble intercellular adhesion molecule-1; SNP, sodium
nitroprusside; sVCAM-1, soluble vascular cell adhesion molecule-1; TAG, triacylglycerol; TC, total cholesterol.
3.2. Effect of Dietary Fat Manipulation and the APOE Genotype on Cardiometabolic Risk Markers
Since low numbers of E2 carriers (E2/E2 and E2/E3) were identified by retrospective genotyping,
they were excluded from the datasets for the (i) chronic (n = 27, SFA diet (n = 12), MUFA diet (n = 5)
and n-6 PUFA diet (n = 10)) and (ii) acute (n = 3, E2/E3) fat manipulations.
3.2.1. Chronic Dietary Fat Composition (DIVAS)
In this analysis, a total of 159 subjects (n = 68 men and 91 women) were included with a mean age
of 44 ± 1 y and mean BMI of 26.4 ± 0.3 kg/m2, of which 107 had the E3/E3 genotype and 52 were E4
carriers. E2 carriers (n = 32) were excluded from this analysis due to relatively small numbers within
each dietary intervention group (Table 2). No diet × genotype interaction was evident for the change
in the primary outcome, %FMD response, or other measures of vascular function during the 16-wk
chronic intervention. A significant diet × genotype interaction was found for the change in fasting
TAG (p = 0.010) but there was no overall diet effect when the APOE3/E3 and E4 carrier groups were
analysed separately. However, there was an indication of a differential responsiveness of fasting TAG
to MUFA intake (but not SFA and n-6 PUFA) with an increase and decrease in TAG concentration in
the E3/E3 and E4 carriers, respectively (p = 0.006; Table 2). APOE genotype was not found to influence
any of the other secondary outcome measures in response to chronic dietary fat intake.
Independent of the 16-wk dietary intervention, genotype effects were observed for the changes
from baseline for HDL-C (p = 0.015), CRP (p = 0.036), as well as P-selectin (p = 0.026; Table 2) where
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there was a reduction in HDL-C and CRP in the E4 carriers as opposed to an increase in the E3/E3 group,
and an increase in P-selectin in the E4 carriers relative to the decrease observed in the E3/E3 group.
3.2.2. Acute Meal Fat Composition (DIVAS-2)
This analysis included 27 postmenopausal women (n = 22, E3/E3 and n = 5, E3/E4), with a mean
age of 58 ± 1 y and mean BMI of 26.1 ± 0.7 kg/m2 (Table 3). The APOE genotype did not influence the
responsiveness of postprandial measures of macrovascular function (%FMD response), microvascular
function (LDI) or arterial stiffness (DVP-SI) to the meal fat composition. However, the postprandial
DVP-RI time response profile showed a significant test fat × time × APOE genotype interaction
(p = 0.014; Figure 1a,b). This was associated with a significant genotype × test fat interaction for the
DVP-RI IAUC (p = 0.030; Figure 2a) with an increase in the DVP-RI IAUC in E4 carriers as opposed to
a reduction in the E3/E3 group (p = 0.002) to the MUFA-rich meal. When data were split according
to the genotype group, there was a significant test fat × time interaction (p = 0.037) and test fat effect
(p = 0.027) in the E4 carriers only, in which the SFA-rich meal reduced the DVP-RI IAUC relative to
MUFA (p = 0.033) and n-6 PUFA-rich (p = 0.028) meals, although these effects were not considered
significant after applying the Bonferroni correction (p ≥ 0.017).
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Table 2. Changes in fasting cardiometabolic risk markers after chronic dietary fat manipulation according to the APOE genotype (DIVAS study).
E3/E3 (n = 107) E4 Carriers (E3/E4 and E4/E4, n = 52) p Value 1
SFA MUFA n-6 PUFA SFA MUFA n-6 PUFA Genotype Diet × Genotype
N 35 36 36 17 17 18
Age, y 44 ± 1 42 ± 2 43 ± 2 44 ± 3 46 ± 3 47 ± 3
BMI, kg/m2 25.8 ± 0.8 26.5 ± 0.8 26.9 ± 0.6 27.5 ± 0.9 26.1 ± 1.0 25.9 ± 0.8
Biochemical profile and estimates of insulin sensitivity/resistance
TC, mmol/L 0.42 ± 0.10 −0.03 ± 0.13 −0.01 ± 0.13 0.21 ± 0.19 −0.29 ± 0.17 −0.19 ± 0.20 0.165 0.760
HDL-C, mmol/L 0.06 ± 0.03 0.04 ± 0.03 0.12 ± 0.04 0.03 ± 0.05 −0.05 ± 0.05 −0.02 ± 0.07 0.015 0.473
LDL-C, mmol/L 0.35 ± 0.09 −0.09 ± 0.11 −0.11 ± 0.10 0.17 ± 0.15 −0.19 ± 0.15 −0.18 ± 0.14 0.401 0.984
TC: HDL-C ratio 0.20 ± 0.08 −0.11 ± 0.07 −0.25 ± 0.07 0.01 ± 0.13 −0.13 ± 0.17 −0.05 ± 0.08 0.703 0.263
LDL-C: HDL-C ratio 0.19 ± 0.08 −0.12 ± 0.07 −0.23 ± 0.07 0.02 ± 0.11 −0.10 ± 0.15 −0.07 ± 0.08 0.652 0.324
TAG, mmol/L −0.00 ± 0.05 0.10 ± 0.06 a −0.07 ± 0.05 0.06 ± 0.14 −0.23 ± 0.10 b 0.08 ± 0.18 0.160 0.010
NEFA, µmol/L −17.6 ± 35.1 −13.6 ± 22.1 −11.1 ± 21.5 −64.8 ± 40.2 46.5 ± 66.3 87.7 ± 26.2 0.413 0.082
Glucose, mmol/L 0.04 ± 0.05 0.07 ± 0.04 0.10 ± 0.06 0.08 ± 0.09 0.01 ± 0.06 0.01 ± 0.11 0.957 0.614
Insulin, pmol/L 1.10 ± 2.73 1.23 ± 1.86 2.67 ± 2.31 0.97 ± 2.77 0.49 ± 1.55 0.71 ± 1.67 0.851 0.857
HOMA-IR 0.07 ± 0.11 0.05 ± 0.08 0.12 ± 0.10 0.05 ± 0.12 0.03 ± 0.07 0.06 ± 0.07 0.821 0.930
rQUICKI 0.00 ± 0.01 −0.00 ± 0.01 −0.01 ± 0.01 0.00 ± 0.01 −0.01 ± 0.01 −0.02 ± 0.01 0.620 0.420
Vascular function
%FMD response −0.55 ± 0.33 0.33 ± 0.44 −0.09 ± 0.36 −0.40 ± 0.49 −0.20 ± 0.69 −0.95 ± 0.73 0.918 0.368
LDI 2
LDI-Ach AUC, PU −460.3 ± 198.1 −2.1 ± 154.6 91.1 ± 119.9 38.5 ± 164.6 −40.7 ± 232.8 −115.4 ± 142.2 0.438 0.134
LDI-SNP AUC, PU −283 ± 173 −187 ± 158 131 ± 127 −28 ± 212 −296 ± 287 187 ± 174 0.233 0.601
DVP-RI, % −1.98 ± 2.34 4.33 ± 2.57 4.29 ± 2.27 −0.27 ± 2.57 1.47 ± 1.91 −4.92 ± 3.52 0.078 0.171
DVP-SI, m/s 0.23 ± 0.32 0.76 ± 0.31 0.22 ± 0.37 0.37 ± 0.37 −0.15 ± 0.32 −0.93 ± 0.43 0.125 0.562
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Table 2. Cont.
E3/E3 (n = 107) E4 Carriers (E3/E4 and E4/E4, n = 52) p Value 1
SFA MUFA n-6 PUFA SFA MUFA n-6 PUFA Genotype Diet × Genotype
Ambulatory blood pressure 3
24-h blood pressure
SBP, mm Hg 1.7 ± 1.3 −1.1 ± 1.3 0.2 ± 1.8 0.5 ± 2.7 −0.9 ± 2.4 −1.3 ± 2.0 0.681 0.860
DBP, mm Hg 1.6 ± 0.9 −0.4 ± 0.9 −0.3 ± 1.1 1.1 ± 1.9 0.9 ± 1.7 −1.4 ± 1.3 0.921 0.813
Pulse pressure, mm Hg 0.2 ± 1.4 −0.7 ± 0.8 0.6 ± 1.0 −0.6 ± 1.1 −1.7 ± 1.4 0.1 ± 1.5 0.502 0.974
Heart rate, bpm 0.8 ± 1.0 0.7 ± 1.1 0.6 ± 1.1 2.8 ± 1.3 1.9 ± 1.8 −1.6 ± 1.6 0.565 0.292
Biomarkers of inflammation and endothelial activation
C-reactive protein, mg/L 0.60 ± 0.60 0.04 ± 0.28 0.024 ± 0.51 −0.14 ± 1.14 −0.25 ± 0.57 −0.79 ± 0.63 0.036 0.786
NOx, µmol/L 0.51 ± 3.22 −1.89 ± 1.52 −1.78 ± 1.87 1.70 ± 3.48 4.43 ± 2.97 −2.27 ± 1.62 0.208 0.073
sVCAM-1, ng/mL −40.0 ± 16.8 11.4 ± 22.2 2.3 ± 13.6 −2.1 ± 16.2 3.9 ± 35.4 25.1 ± 25.2 0.063 0.451
sICAM-1, ng/mL −1.4 ± 4.2 1.3 ± 3.6 1.5 ± 6.3 5.2 ± 6.6 15.3 ± 8.2 12.8 ± 5.1 0.100 0.836
E-selectin, ng/mL 0.41 ± 1.39 −2.90 ± 1.15 −0.63 ± 1.03 0.70 ± 2.01 −3.03 ± 1.86 −0.24 ± 1.43 0.827 0.881
P-selectin, ng/mL −0.94 ± 1.70 −1.94 ± 1.06 −3.49 ± 1.23 3.63 ± 1.74 −1.18 ± 2.32 0.21 ± 1.44 0.026 0.403
Values represent mean ± SEM, change from baseline after post intervention (week 16). Total n = 131–157, with n = 89–107 E3/E3 and n = 4252 E4 carriers per outcome. E2/E4 and E2 = E2/E2
+ E2/E3 individuals were excluded from the analysis. 1 Data analysed by univariate general linear model (ANCOVA) by using the difference from baseline (post-intervention (Visit 2)
minus baseline (Visit 1)) as the dependent variable, with genotype, sex and intervention diet as fixed factors and with baseline data for the variable of interest, age and BMI as covariates.
The interaction term was added to the model to assess the APOE genotype and diet interaction. a,b Different superscript letters within a row indicate significant differences between
genotype groups (p ≤ 0.017). 2 LDI-Ach and LDI-SNP were expressed as area under the curve (AUC) for the 20-scan protocol. Incremental AUC (IAUC) was also determined for the
20-scan protocol but differences between test fats for subsequent AUC and IAUC were not significant (data not shown). 3 Day and night ambulatory blood pressure were analysed and no
significant effects were found (data not shown). Abbreviations: Ach, acetylcholine; PU, perfusion units; AUC, area under the curve, BMI, body mass index; DBP, diastolic blood pressure;
DVP-RI, digital volume pulse reflection index; DVP-SI, digital volume pulse stiffness index; DIVAS, Dietary Intervention and vascular function; FMD, flow mediated dilatation; HDL-C,
high-density lipoprotein cholesterol; HOMA, quantitative insulin resistance index; LDI, laser Doppler imaging; LDL-C, low-density lipoprotein cholesterol; MUFA, monounsaturated fatty
acids; NEFA, non-esterified fatty acid; NOx, total nitrites and nitrates; PUFA, polyunsaturated fatty acids; rQUICKI, revised quantitative insulin sensitivity index; SBP, systolic blood
pressure; SFA, saturated fatty acids; sICAM-1, soluble intercellular cell adhesion molecule 1; SNP, sodium nitroprusside; sVCAM-1, soluble vascular cell adhesion molecule 1; TAG,
triacylglycerol; TC, total cholesterol.
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Table 3. Summary measures for the impact of the APOE genotype on postprandial cardiometabolic risk markers after sequential meals of varying fat composition
(DIVAS-2 study).
E3/E3 (n = 22) E3/E4 (n = 5) p Value 1
SFA MUFA n-6 PUFA SFA MUFA n-6 PUFA Genotype Test Fat × Genotype
Biochemical measures 2
TAG, mmol/L
AUC 942 ± 90 1022 ± 87 1035 ± 124 1063 ± 186 1022 ± 164 1125 ± 299 0.702 0.683
IAUC 320 ± 52 360 ± 53 361 ± 77 402 ± 94 403 ± 126 386 ± 115 0.702 0.828
NEFA, µmol/L
AUC 143.5 ± 8.4 136.1 ± 11.3 126.9 ± 7.3 108.6 ± 16.1 102.4 ± 13.3 116.9 ± 21.1 0.147 0.382
IAUC −73.5 ± 12.3 −87.9 ± 12.7 −83.7 ± 12.7 −75.2 ± 29.6 −12.6 ± 16.9 −62.0 ± 29.8 0.802 0.111
Apo B, mg/mL
AUC 473 ± 18 469 ± 22 480 ± 25 549 ± 32 561 ± 50 512 ± 34 0.329 0.134
IAUC 62.4 ± 4.3 50.7 ± 3.2 −12.4 ± 5.2 −11.6 ± 2.5 −23.3 ± 9.8 31.3 ± 8.3 0.197 0.022 3
Glucose, mmol/L
AUC 942 ± 90 1022 ± 87 1035 ± 124 1063 ± 186 1022 ± 164 1125 ± 299 0.666 0.299
IAUC 320 ± 52 360 ± 53 361 ± 77 402 ± 94 403 ± 126 386 ± 115 0.342 0.523
Insulin, µmol/L
AUC 913 ± 8 877 ± 11 821 ± 9 948 ± 19 951 ± 15 952 ± 18 0.640 0.814
IAUC 881 ± 8 831 ± 9 779 ± 6 795 ± 16 783 ± 12 753 ± 14 0.610 0.750
Vascular function 2
% FMD response
AUC 1939 ± 148 2305 ± 191 2131 ± 191 2105 ± 235 2629 ± 486 2329 ± 218 0.510 0.898
IAUC −149 ± 183 156 ± 261 114 ± 189 345 ± 335 431 ± 279 79 ± 281 0.433 0.683
LDI-Ach 4, AU × 103
AUC 742 ± 47 766 ± 56 772 ± 50 871 ± 101 973 ± 320 941 ± 160 0.888 0.931
IAUC 7.8 ± 35.1 −8.1 ± 62.2 −11.0 ± 53.9 −46.4 ± 101.6 −70.0 ± 132.3 −21.8 ± 127.9 0.088 0.975
LDI-SNP 4, AU × 103
AUC 755 ± 57 807 ± 66 652 ± 33 802 ± 99 957 ± 264 113 ± 227 0.690 0.083
IAUC 318 ± 60 −101 ± 59 −331 ± 61 −118 ± 74 −286 ± 117 −505 ± 171 0.754 0.624
DVP-RI, % × 103
AUC 26.1 ± 1.0 24.7 ± 0.7 25.5 ± 0.9 25.9 ± 0.8 27.6 ± 1.5 27.1 ± 2.7 0.407 0.392
IAUC −1.7 ± 0.8 −3.2 ± 0.7 −2.4 ± 0.6 −3.3 ± 0.9 1.2 ± 0.7 0.2 ± 1.0 0.055 0.030 3
DVP-SI, m/s
AUC 3193 ± 121 3074 ± 110 3169 ± 114 3463 ± 178 3505 ± 277 3617 ± 415 0.177 0.735
IAUC 14.6 ± 97.6 −181.2 ± 110.1 40.5 ± 120.4 171.3 ± 178.4 −44.0 ± 241.3 226.5 ± 154.4 0.373 0.987
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Table 3. Cont.
E3/E3 (n = 22) E3/E4 (n = 5) p Value 1
SFA MUFA n-6 PUFA SFA MUFA n-6 PUFA Genotype Test Fat × Genotype
SBP, mmHg × 103
AUC 56.3 ± 1.5 57.1 ± 1.4 57.1 ± 1.6 58.9 ± 3.5 56.7 ± 2.5 58.3 ± 3.5 0.716 0.267
IAUC −2.5 ± 0.6 −4.8 ± 0.6 −3.3 ± 0.7 −3.6 ± 0.7 −3.2 ± 1.5 −4.2 ± 1.0 0.914 0.178
DBP, mmHg × 103
AUC 32.9 ± 3.3 33.1 ± 3.3 33.3 ± 3.3 32.9 ± 1.2 31.9 ± 1.0 32.0 ± 1.4 0.686 0.341
IAUC −1.1 ± 0.4 −2.2 ± 0.3 −1.5 ± 0.3 −1.0 ± 0.6 −1.7 ± 0.3 −9.7 ± 0.7 0.442 0.867
Biomarkers of endothelial activation 2
NOx, µmol/L
AUC 5820 ± 482 5962 ± 708 5119 ± 389 6308 ± 258 6278 ± 258 6084 ± 1330 0.288 0.996
IAUC −1618 ± 231 −1446 ± 370 −1057 ± 219 −2165 ± 521 −3015 ± 695 −1762 ± 393 0.078 0.318
sVCAM-1, µg/mL
AUC 263.0 ± 7.1 270.7 ± 9.2 256.9 ± 7.3 263.4 ± 22.2 243.0 ± 14.6 243.5 ± 16.4 0.431 0.118
IAUC 4.2 ± 5.0 3.1 ± 4.6 −4.7 ± 2.9 3.9 ± 4.9 −8.5 ± 9.2 −9.6 ± 8.1 0.360 0.707
sICAM-1, µg/mL
AUC 86.3 ± 3.1 876.9 ± 3.8 702.5 ± 5.7 715.3 ± 3.5 717.9 ± 2.9 588.9 ± 6.1 0.141 0.775
IAUC −3.2 ± 1.3 −0.2 ± 1.5 −18.1 ± 4.1 0.4 ± 6.4 0.6 ± 2.5 −15.9 ± 10.0 0.581 0.881
E-selectin, µg/mL
AUC 10.7 ± 0.9 11.0 ± 0.9 10.6 ± 0.8 11.4 ± 1.6 11.9 ± 1.5 10.6 ± 1.6 0.694 0.407
IAUC −0.4 ± 0.3 −0.01 ± 0.2 −0.2 ± 0.1 −0.3 ± 0.3 0.6 ± 0.4 0.5 ± 0.01 0.065 0.472
P-selectin, µg/mL
AUC 13.0 ± 0.7 13.0 ± 0.9 13.1 ± 0.8 14.7 ± 1.8 16.5 ± 2.9 14.8 ± 2.1 0.300 0.131
IAUC −0.6 ± 0.3 0.01 ± 0.2 −0.01 ± 0.3 −0.07 ± 0.0 1.3 ± 1.3 0.3 ± 0.4 0.078 0.737
Values are mean ± SEM, for the E3/E3 and E3/E4 groups. E2 carriers and E2/E4 individuals were excluded from the analysis. 1 p value refers to the interaction between summary measures
and the APOE genotype. A mixed factor repeated measures ANOVA determined the effects of the test fats on summary measures. For this, test fat and time were included as within-subject
factors and genotype as the between group factor. 2 Units for AUC and IAUC expressed as biomarker units × time interval. The time interval for AUC and IAUC represents 480 min for
TAG, apoB, glucose and insulin; 120–480 min for NEFA; 420 min for FMD and biomarkers of endothelial activation; 450 min for DBP, SBP, DVP-SI, DVP-RI and LDI. 3 For significant test fat
× genotype interactions, independent samples t-test was performed to identify the effects of genotype for each test fat separately. 4 LDI-Ach and LDI-SNP were expressed as AUC for the
20-scan protocol. IAUC was also determined for the 20-scan protocol but differences between test fats for subsequent AUC and IAUC were not significant (data not shown). Abbreviations:
Ach, acetylcholine; apoB, apolipoprotein B; AU, arbitrary units; AUC, area under the curve; DBP, diastolic blood pressure; DIVAS, Dietary Intervention and vascular function; DVP, digital
volume pulse; DVP-RI, DVP-reflection index; DVP-SI, DVP-stiffness index; FMD, flow mediated dilatation; IAUC, incremental AUC; LDI, laser Doppler imaging; NEFA, non-esterified
fatty acids; NOx, total nitrite and nitrate concentrations; SBP, systolic blood pressure; sICAM-1, soluble intercellular cell adhesion molecule-1; SNP, sodium nitroprusside; sVCAM-1,
soluble vascular cell adhesion molecule-1.
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Figure 1. Mean ± SEM for the postprandial digital volume pulse reflection index (DVP-RI) response 
in (a) the E3/E3 group (n = 22) and (b) E4 carriers (n = 5) response following sequential meals 
(breakfast: 0 min and lunch: 330 min) enriched in saturated fatty acids (SFA; ), monounsaturated 
fatty acids (MUFA; ) and n-6 polyunsaturated fatty acids (PUFA; ). Two-way repeated measures 
ANOVA revealed a significant test fat × time × genotype interaction (p = 0.014) for the DVP-RI 
response. There was also a significant genotype × test fat interaction for the DVP-RI IAUC (p = 0.030).  
There was a test fat × genotype interaction for the total serum postprandial apoB response IAUC 
(p = 0.022), with a tendency for higher IAUC after the n-6 PUFA than MUFA and SFA-rich meals (p = 
0.068) in E4 carriers only (Table 3, Figure 2b). However, there were differential effects on the 
responsiveness of the genotype groups to the MUFA-rich meals, with a reduction in the total apoB 
IAUC in E4 carriers compared to an increase in the E3/E3 group (p = 0.002). For all other 
cardiometabolic risk markers, the APOE genotype did not appear to influence the postprandial 
responses to the test fats. 
. t e postprandial digital volume pulse reflection index (DVP-RI) response in
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0 min and lunch: 330 min) enriched in saturated f tty ci s (SFA; ), monounsaturated fatty acids
(MUFA; ) and n-6 polyunsaturated fat y cids (PUFA; ). Two-way repeated measures ANOVA
revealed a significant test fat × tim × genotype interaction (p = 0.014) for the DVP-RI response. There
was also a significant genotype × test fat interaction for he DVP-RI IAUC (p = 0.030).
There as a test fat × genotype interaction for the total serum postprandial apoB response IAUC (p
= 0.022), with a tendency for higher IAUC after the n-6 PUFA than MUFA and SFA-rich meals (p = 0.068)
in E4 carriers only (Table 3, Figure 2b). However, there were differential effects on the responsiveness
of the genotype groups to the MUFA-rich meals, with a reduction in the total apoB IAUC in E4 carriers
compared to an increase in the E3/E3 group (p = 0.002). For all other cardiometabolic risk markers, the
APOE genotype did not appear to influence the postprandial responses to the test fats.
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Figure 2. Incremental area under the curve (IAUC) for the postprandial (a) digital volume pulse 
reflection index (DVP-RI) and (b) total serum apolipoprotein (apo)B response according to APOE in 
the postmenopausal women following sequential meals (breakfast: 0 min and lunch: 330 min) 
enriched in saturated fatty acids (SFA), monounsaturated fatty acids (MUFA) and n-6 
polyunsaturated fatty acids (PUFA). Data represent mean ± SEM for the APOE3/E3 group (black bars, 
n = 17) and APOE4 carriers (white bars, n = 4). There was a significant genotype × test fat interaction 
for the DVP-RI IAUC (p = 0.030) with an increase in the DVP-RI IAUC in E4 carriers compared to a 
reduction in the E3/E3 group (* p = 0.002) to the MUFA-rich meal. There was a significant genotype × 
test fat interaction for the postprandial total apoB IAUC (p = 0.022) with a reduction in the apoB IAUC 
in E4 carriers compared to an increase in the E3/E3 group after the MUFA-rich meals (** p = 0.002). 
4. Discussion 
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in saturated fatty acids (SFA), monounsaturated fatty acids (MUFA) and n-6 polyunsaturate fatty
acids (PUFA). Dat represent mean ± SEM for the APOE3/E3 group (black bars, n = 17) and APOE4
carriers (white bars, n = 4). There was a significant genotype × test fat interaction for the DVP-RI IAUC
(p = 0.030) with an increase in the DVP-RI IAUC in E4 carriers compared to a reduction in the E3/E3
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4. Discussion
It has been suggested that personalised gene-based dietary advice is more useful than general
dietary guidelines [29] and more effective at motivating dietary change [30]. It is, therefore, important
to investigate common single nucleotide polymorphisms related with CVD risk that impact on response
to key population dietary fat recommendations for CVD risk reduction. To our knowledge, this is the
first data analysis that has examined both the chronic and acute impact of dietary fat manipulation on
novel and established cardiometabolic risk markers according to the APOE genotype.
In the present baseline analysis, the higher fasting TC and LDL-C concentrations, and TC: HDL-C
and LDL-C:HDL-C ratios were more evident in E4 carriers than E2 carriers and the E3/E3 wild-type
genotype group, which confirms previous studies [4,5,20,31–33]. A number of possible mechanisms
could explain the higher fasting TC and LDL-C concentrations in E4 carriers [11]. ApoE is present
on TAG-rich lipoproteins (chylomicrons and very low-density lipoproteins (VLDL)) and HDL, but
not LDL particles and is involved with lipid transport and receptor mediated clearance. The apoE4
protein isoform has selective affinity for larger TAG-rich lipoproteins, for example dietary derived
chylomicrons, which would be expected to increase the competition with LDL for the LDL receptor
mediated clearance, increasing circulating LDL-C concentrations [34,35]. However, the lower binding
affinity of the E2 isoform to the hepatic LDL receptor, compared with both E3 and E4 would be expected
to slow the clearance of VLDL and dietary chylomicron remnants, and increase LDL clearance leading
to typically lower concentrations of TC and LDL-C, yet higher postprandial TAG in E2 carriers [36].
Furthermore, the lipolytic conversion of VLDL remnants to LDL is reportedly faster in E4 carriers [37].
All of these mechanisms could contribute to varying extents to the higher fasted TC and LDL-C
concentrations in E4 carriers in the current study, in the order of E4 carriers > E3/E3 group > E2 carriers.
We also observed genotype effects on a biomarker of inflammation, with E2 carriers having greater
fasting CRP concentrations compared with E4 carriers. Additionally, serum CRP was lower in E4
carriers, a finding that has also been observed in other studies [4,38–45]. Although both fasting LDL-C
and CRP are recognised as independent CVD risk factors [46], some recent literature has indicated that
elevated CRP does not raise the risk of CVD events as much as originally thought [47–49]. Therefore,
the greater CVD risk previously reported in E4 carriers could be due to increased TC and LDL-C
concentrations despite lower CRP [3,5]. Findings from an experimental study have reported apoE
to influence immune cell function, with APOE4 carriers more predisposed to a pro-inflammatory
phenotype [50]. Further studies incorporating markers of immune function are needed to confirm
these findings and determine the mechanisms linking the APOE genotype with inflammation.
The present study found a limited impact of the APOE genotype on the responsiveness of
cardiometabolic risk markers to differences in chronic fat intake, although there was some evidence
that E4 carriers were more sensitive to the TAG lowering effect of a diet in which 8 %TE SFA was
replaced with MUFA. Analysis of data from the Diet, genomics and metabolic syndrome: an integrated
nutrition, agro-food, social and economic analysis (LIPGENE; n = 442 men and women classified
with metabolic syndrome) and RISCK (n = 389 men and women ‘at risk’ from metabolic syndrome)
studies revealed no differences in fasted TAG following a 19 and 17 %TE MUFA diet for 12 or 16 weeks,
respectively, according to the APOE genotype [33]. However, analysis of the data from the LIPGENE
study was performed according to plasma fatty acids concentrations, rather than dietary intake, and
although circulating fatty acids (particularly PUFA) can reflect consumption, only weak correlations
between dietary and plasma SFA and MUFA exist due to endogenous de novo synthesis of these fatty
acids from lipid and non-lipid sources [51]. Furthermore, a study in 84 young healthy students with a
mean age of 22.5 years (66 APOE3/3, 8 APOE4/E3 and 10 APOE2/E3) following a 22 %TE MUFA diet for
4 weeks also reported no difference in TAG according to the APOE genotype, although there were
low numbers of E4 carriers and could have been underpowered for these comparisons as a result
of retrospective genotyping [52]. Additional research is required to confirm the effects of different
unsaturated fats on fasting TAG according to APOE genotype.
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Our study found the APOE genotype had a limited impact on postprandial lipid levels in relation
to dietary fat manipulation, which is in agreement with our SATurated fat and gene APOE (SATgene)
study [7], which prospectively genotyped according to APOE (E3/E3 and E4 carriers). However, in
the current study a greater reduction in the postprandial apoB response (IAUC) was identified in E4
carriers compared with the E3/3 group after the MUFA-rich meals, although no difference in TAG
responses were evident. This was surprising since TAG is transported in chylomicrons (containing
apoB48) and VLDL (containing apoB100) and postprandial total apoB generally reflects concentrations
of these TAG-rich lipoproteins. In contrast, Cardona et al. investigated adults identified as having the
metabolic syndrome and found no impact on apoB measured 4 h postprandially after a MUFA-rich
meal, but observed E2 and E4 carriers combined to have higher postprandial TAG, with E2 carriers
having the highest TAG [19]. Postprandial differences in TAG were observed after a SFA-rich test meal
in E4 carriers compared with E3/E3, although these were reported to be reflective of the higher baseline
TAG concentrations [18]. In support of the importance of fasted TAG concentrations, the significantly
higher postprandial TAG concentrations in E4 carriers compared with E3/E3 in response to a high fat
meal were attenuated when the incremental response was calculated [17].
We found no differences in measures of fasted macrovascular (%FMD response) or microvascular
(LDI) reactivity, however we provided novel evidence of a difference in baseline (fasting) arterial
stiffness according to the APOE genotype. Vascular dysfunction is considered to be an important risk
factor for CVD and associations have been reported between cardiovascular mortality and related
vascular conditions, including hypertension [53], arterial stiffness [54] and endothelial dependent
vasodilation [55], and arterial stiffness is related to chronic inflammation and dyslipidaemia, particularly
elevated TAG [56], often found in E2 carriers, with E2 homozygotes having a higher risk of Type III
hyperlipoproteinemia, which leads to progressive atherosclerosis [35,38]. The higher arterial stiffness
(measured by DVP-SI) observed in the E2 carriers, compared with E3/E3 in our study, might have
reflected the higher inflammatory marker (CRP) in our E2 carriers, although further confirmation
of this association is required. However, there was no diet/meal fat and APOE genotype interaction
observed for arterial stiffness. This is perhaps not surprising as arterial stiffness is a progressively slow
process and longer term dietary fat manipulation may be necessary before differences are observed [57].
With regards to vascular function, this study is the first to report that the APOE genotype had a
limited impact on fasting and postprandial measures of vascular function after chronic and acute fat
manipulation, respectively. Yet, a reduction in DVP-RI was observed in the E3/E3 compared with E4
carriers after the MUFA-rich meals, which indicates that differences in small vessel tone after meal
ingestion are dependent on genotype, although the mechanism of action and the clinical relevance
are unclear.
This study is novel, being the first to investigate the effect of the APOE genotype on vascular
function and cardiometabolic risk markers at baseline and in response to chronic and acute dietary fat
manipulation. Furthermore, there are a number of strengths in the study design of both the chronic and
acute interventions. Firstly, the target intakes of SFA in the unsaturated fat diets in the chronic DIVAS
study were compliant with the current population recommendation for CVD risk reduction of ≤10 %TE
SFA. Secondly, the chronic diets were followed for a longer duration (16 weeks) than many published
dietary fat interventions investigating the effects on vascular function as the primary outcome. Moreover,
the acute study (DIVAS-2) used a two meal sequential postprandial protocol, which is considered
superior to a single test meal challenge as it better represents a habitual meal intake pattern [58,59].
Since the genotyping was performed retrospectively, the number of participants who carried the E2
allele was low in both the chronic and acute datasets, which necessitated removal of E2 carriers, and
could be considered as a limitation. Furthermore, there was a small sample size for E4 carriers in the
DIVAS-2 study. In addition, as only postmenopausal women were recruited for the postprandial analysis
(DIVAS-2), our postprandial findings may not relate to other population subgroups, including men
and premenopausal women. However, both the baseline and chronic data analyses included a wider
population, consisting of both men and pre- and postmenopausal women in the UK.
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In conclusion, this study has confirmed previous findings that the APOE genotype is associated
with fasting lipid profile and CRP and presents novel evidence of an association between the APOE
genotype with fasting DVP-SI. Moreover, our findings revealed a limited influence of the APOE
genotype on the responsiveness of novel and established cardiometabolic risk markers to chronic
and acute fat manipulation. However, further studies are warranted using prospective genotyping in
relation to dietary fat recommendations for CVD risk reduction to confirm the findings in relation to
the effects of the APOE genotype on markers of vascular functions, lipids and inflammation.
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AUC Area under the curve
BMI Body mass index
CRP C-reactive protein
CVD Cardiovascular disease
DBP Diastolic blood pressure
DIVAS Dietary intervention and vascular function
DVP Digital volume pulse
DVP-RI DVP reflection index
DVP-SI DVP stiffness index
FMD Flow mediated dilatation
HDL-C High-density lipoprotein cholesterol
HOMA-IR Quantitative insulin resistance index
IAUC Incremental AUC
LDI Laser Doppler imaging
LDL-C Low-density lipoprotein cholesterol
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PUFA Polyunsaturated fatty acids
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sICAM-1 Soluble intercellular cell adhesion molecule-1
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